TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 43)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
TABLE 1 IMMUNOTHERAPY DRUGS MARKET: INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 SEGMENTS COVERED
FIGURE 1 IMMUNOTHERAPY DRUGS MARKET: SEGMENTS COVERED
1.3.2 REGIONS COVERED
FIGURE 2 IMMUNOTHERAPY DRUGS MARKET: REGIONS COVERED
1.3.3 YEARS CONSIDERED
FIGURE 3 IMMUNOTHERAPY DRUGS MARKET: YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.3.5 UNITS CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.5.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY (Page No. - 48)
2.1 RESEARCH DATA
FIGURE 4 IMMUNOTHERAPY DRUGS MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
FIGURE 5 IMMUNOTHERAPY DRUGS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 6 IMMUNOTHERAPY DRUGS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
2.2.1 COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
FIGURE 7 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2023
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTIONS
FIGURE 9 IMMUNOTHERAPY DRUGS MARKET: CAGR PROJECTIONS
FIGURE 10 IMMUNOTHERAPY DRUGS MARKET: ANALYSIS OF DEMAND-SIDE DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.4 DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
TABLE 2 IMMUNOTHERAPY DRUGS MARKET: RISK ANALYSIS
2.7 IMPACT OF ECONOMIC RECESSION ON IMMUNOTHERAPY DRUGS MARKET
TABLE 3 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
3 EXECUTIVE SUMMARY (Page No. - 58)
FIGURE 12 IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
FIGURE 13 IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2024 VS. 2029 (USD BILLION)
FIGURE 14 IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD BILLION)
FIGURE 15 IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2024 VS. 2029 (USD BILLION)
FIGURE 16 IMMUNOTHERAPY DRUGS MARKET: REGIONAL SNAPSHOT
4 PREMIUM INSIGHTS (Page No. - 62)
4.1 IMMUNOTHERAPY DRUGS MARKET OVERVIEW
FIGURE 17 TECHNOLOGICAL ADVANCEMENTS IN ANTIBODY ENGINEERING TO DRIVE MARKET
4.2 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE AND COUNTRY (2023)
FIGURE 18 US AND ANTIBODY DRUGS SEGMENT COMMANDED LARGEST MARKET SHARE IN 2023
4.3 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
FIGURE 19 ANTIBODY DRUGS TO DOMINATE NORTH AMERICAN MARKET DURING STUDY PERIOD
5 MARKET OVERVIEW (Page No. - 65)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 IMMUNOTHERAPY DRUGS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 4 IMMUNOTHERAPY DRUGS MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Technological advancements in antibody engineering
5.2.1.2 Increasing demand for antibody therapeutics in clinical cancer treatment
TABLE 5 NUMBER OF APPROVED PRODUCTS BY US FDA/EMA, 2015–2023
5.2.1.3 Growing demand for personalized medicines and targeted therapies
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulatory approval process for immunotherapy drugs
5.2.2.2 High cost of monoclonal antibody therapeutics
5.2.3 OPPORTUNITIES
5.2.3.1 Rising number of approvals for CAR T-cell therapies
TABLE 6 APPROVED AUTOLOGOUS CAR T-CELL THERAPIES
5.2.3.2 Increasing collaborations among pharmaceutical companies, CROs, CDMOs, and academic institutes
5.2.4 CHALLENGES
5.2.4.1 Complexities in development of antibody therapeutics
5.3 PORTER’S FIVE FORCES ANALYSIS
FIGURE 21 IMMUNOTHERAPY DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 7 IMMUNOTHERAPY DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 THREAT OF SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 KEY STAKEHOLDERS & BUYING CRITERIA
5.4.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 22 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF IMMUNOTHERAPY DRUGS
5.4.2 KEY BUYING CRITERIA
FIGURE 23 KEY BUYING CRITERIA FOR HOSPITALS AND LONG-TERM CARE FACILITIES
5.5 VALUE CHAIN ANALYSIS
FIGURE 24 IMMUNOTHERAPY DRUGS MARKET: VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 25 IMMUNOTHERAPY DRUGS MARKET: SUPPLY CHAIN ANALYSIS
5.7 PRICING ANALYSIS
5.7.1 AVERAGE SELLING PRICE OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER
FIGURE 26 AVERAGE SELLING PRICE TREND OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER
5.7.2 AVERAGE COST RANGE OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER, 2021–2023
TABLE 8 AVERAGE COST RANGE OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER, 2021–2023
5.7.3 INDICATIVE PRICE OF ANTIBODY THERAPEUTICS, BY ROUTE OF ADMINISTRATION
TABLE 9 INDICATIVE PRICE OF ANTIBODY THERAPEUTICS, BY ROUTE OF ADMINISTRATION
5.7.4 INDICATIVE PRICE OF IMMUNOTHERAPY DRUGS, BY REGION
TABLE 10 INDICATIVE PRICE OF IMMUNOTHERAPY DRUGS, BY REGION
5.8 ECOSYSTEM ANALYSIS
FIGURE 27 IMMUNOTHERAPY DRUGS MARKET: ECOSYSTEM MAP
5.8.1 ROLE IN ECOSYSTEM (SUPPLY AND DEMAND SIDES)
TABLE 11 IMMUNOTHERAPY DRUGS MARKET: ROLE IN ECOSYSTEM (SUPPLY AND DEMAND SIDES)
5.9 PATENT ANALYSIS
FIGURE 28 PATENT APPLICATIONS FOR IMMUNOTHERAPY DRUGS (JANUARY 2012–DECEMBER 2023)
5.10 TECHNOLOGY ANALYSIS
5.10.1 KEY TECHNOLOGIES
5.10.1.1 Gene editing
5.10.1.2 High-throughput screening
5.10.1.3 Next-generation sequencing
5.10.2 COMPLEMENTARY TECHNOLOGIES
5.10.2.1 Nanotechnology
5.10.2.2 Artificial intelligence
5.11 INVESTMENT & FUNDING SCENARIO
5.11.1 MAJOR INVESTMENTS AND FUNDING
TABLE 12 IMMUNOTHERAPY DRUGS MARKET: MAJOR INVESTMENTS AND FUNDING, JANUARY 2021–MAY 2024
5.11.2 OTHER INVESTMENTS AND FUNDING
5.12 KEY CONFERENCES & EVENTS, 2024–2025
TABLE 13 IMMUNOTHERAPY DRUGS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2024–DECEMBER 2025
5.13 CASE STUDY ANALYSIS
5.13.1 CASE STUDY 1: EFFICACY OF KEYTRUDA IN CANCER TREATMENT
5.13.2 CASE STUDY 2: EFFECTIVE USE OF LYNPARZA IN PROSTATE CANCER TREATMENT
5.13.3 CASE STUDY 3: CLINICAL TRIALS OF ORPATHYS (SAVOLITINIB)
5.14 REGULATORY LANDSCAPE
5.14.1 REGULATORY ANALYSIS
5.14.1.1 North America
5.14.1.1.1 US
5.14.1.1.2 Canada
5.14.1.2 Europe
5.14.1.2.1 Germany
5.14.1.2.2 UK
5.14.1.2.3 Rest of Europe
5.14.1.3 Asia Pacific
5.14.1.3.1 China
5.14.1.3.2 Japan
5.14.1.3.3 South Korea
5.14.1.3.4 Australia
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14.2.1 North America
TABLE 14 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14.2.2 Europe
TABLE 15 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14.2.3 Asia Pacific
TABLE 16 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14.2.4 Latin America
TABLE 17 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14.2.5 Middle East & Africa
TABLE 18 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6 IMMUNOTHERAPY DRUGS MARKET, BY TYPE (Page No. - 107)
6.1 INTRODUCTION
TABLE 19 IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 20 IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (UNITS)
6.2 ANTIBODY DRUGS
6.2.1 ROBUST CLINICAL PIPELINE OF ANTIBODY THERAPEUTICS TO SUPPORT MARKET GROWTH
TABLE 21 ANTIBODY DRUGS MARKET, BY REGION, 2022–2029 (USD BILLION)
TABLE 22 NORTH AMERICA: ANTIBODY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 23 EUROPE: ANTIBODY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 24 ASIA PACIFIC: ANTIBODY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 25 LATIN AMERICA: ANTIBODY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 26 MIDDLE EAST: ANTIBODY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 27 GCC COUNTRIES: ANTIBODY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
6.3 INHIBITOR DRUGS
6.3.1 INCREASED FOCUS ON DEVELOPMENT OF TARGET MEDICINES AND COMBINATION THERAPIES TO FUEL MARKET GROWTH
TABLE 28 INHIBITOR DRUGS MARKET, 2022–2029 (USD BILLION)
TABLE 29 NORTH AMERICA: INHIBITOR DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 30 EUROPE: INHIBITOR DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 31 ASIA PACIFIC: INHIBITOR DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 32 LATIN AMERICA: INHIBITOR DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 33 MIDDLE EAST: INHIBITOR DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 34 GCC COUNTRIES: INHIBITOR DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
6.4 INTERFERONS & INTERLEUKINS
6.4.1 INCREASED FOCUS ON R&D AND DEVELOPMENT OF NEW IMMUNOTHERAPY DRUGS TO AUGMENT MARKET GROWTH
TABLE 35 INTERFERONS & INTERLEUKINS MARKET, BY REGION, 2022–2029 (USD BILLION)
TABLE 36 NORTH AMERICA: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 37 EUROPE: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 38 ASIA PACIFIC: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 39 LATIN AMERICA: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 40 MIDDLE EAST: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 41 GCC COUNTRIES: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
6.5 CANCER VACCINES
6.5.1 RISING FOCUS ON RESEARCH ACTIVITIES AND CLINICAL TRIALS TO SPUR MARKET GROWTH
TABLE 42 CANCER VACCINES MARKET, BY REGION, 2022–2029 (USD BILLION)
TABLE 43 NORTH AMERICA: CANCER VACCINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 44 EUROPE: CANCER VACCINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 45 ASIA PACIFIC: CANCER VACCINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 46 LATIN AMERICA: CANCER VACCINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 47 MIDDLE EAST: CANCER VACCINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 48 GCC COUNTRIES: CANCER VACCINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
6.6 OTHER IMMUNOTHERAPY DRUGS
TABLE 49 OTHER IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2022–2029 (USD BILLION)
TABLE 50 NORTH AMERICA: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 51 EUROPE: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 52 ASIA PACIFIC: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 53 LATIN AMERICA: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 54 MIDDLE EAST: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 55 GCC COUNTRIES: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
7 IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION (Page No. - 126)
7.1 INTRODUCTION
TABLE 56 IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
7.2 CANCER
7.2.1 LARGE R&D SPENDING AND HIGH GOVERNMENT INVESTMENTS TO DRIVE MARKET
TABLE 57 IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY REGION, 2022–2029 (USD BILLION)
TABLE 58 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 59 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 60 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 61 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 62 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY REGION, 2022–2029 (USD BILLION)
TABLE 63 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD BILLION)
7.3 AUTOIMMUNE & INFLAMMATORY DISEASES
7.3.1 ADVANCEMENTS IN MOLECULAR ENGINEERING AND INTRODUCTION OF BIOLOGICAL DRUGS TO PROPEL MARKET GROWTH
TABLE 64 IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2022–2029 (USD BILLION)
TABLE 65 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 66 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 67 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 68 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 69 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2022–2029 (USD BILLION)
TABLE 70 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)
7.4 HEMATOLOGY
7.4.1 INCREASED R&D IN CELL-BASED THERAPIES, MONOCLONAL ANTIBODIES, AND IMMUNE CHECKPOINT INHIBITORS TO AID MARKET GROWTH
TABLE 71 IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD BILLION)
TABLE 72 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 73 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 74 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 75 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 76 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD BILLION)
TABLE 77 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
7.5 OSTEOLOGY
7.5.1 GROWING INCIDENCE OF OSTEOPOROSIS-RELATED FRACTURES TO DRIVE MARKET
TABLE 78 IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY REGION, 2022–2029 (USD BILLION)
TABLE 79 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 80 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 81 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 82 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 83 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY REGION, 2022–2029 (USD BILLION)
TABLE 84 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
7.6 NEUROLOGY
7.6.1 ADVANCEMENTS IN NEUROLOGICAL DRUG DEVELOPMENT TO BOOST MARKET GROWTH
TABLE 85 IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY REGION, 2022–2029 (USD BILLION)
TABLE 86 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 87 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 88 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 89 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 90 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY REGION, 2022–2029 (USD BILLION)
TABLE 91 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION)
7.7 OTHER APPLICATIONS
TABLE 92 IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD BILLION)
TABLE 93 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 94 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 95 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 96 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 97 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD BILLION)
TABLE 98 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION)
8 IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 148)
8.1 INTRODUCTION
TABLE 99 IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
8.2 INTRAVENOUS ROUTE OF ADMINISTRATION
8.2.1 DIRECT DELIVERY OF THERAPEUTIC DOSAGE TO PROPEL MARKET GROWTH
TABLE 100 IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD BILLION)
TABLE 101 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 102 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 103 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 104 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 105 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD BILLION)
TABLE 106 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
8.3 SUBCUTANEOUS ROUTE OF ADMINISTRATION
8.3.1 ENHANCED PATIENT ADHERENCE AND LOW HEALTHCARE COSTS TO AID MARKET GROWTH
TABLE 107 IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD BILLION)
TABLE 108 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 109 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 110 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 111 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 112 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 USD BILLION)
TABLE 113 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
8.4 OTHER ROUTES OF ADMINISTRATION
TABLE 114 IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD BILLION)
TABLE 115 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 116 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 117 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 118 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 119 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD BILLION)
TABLE 120 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)
9 IMMUNOTHERAPY DRUGS MARKET, BY END USER (Page No. - 160)
9.1 INTRODUCTION
TABLE 121 IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
9.2 HOSPITALS
9.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT MARKET GROWTH
TABLE 122 IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD BILLION)
TABLE 123 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 124 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 125 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 126 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 127 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD BILLION)
TABLE 128 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION)
9.3 LONG-TERM CARE FACILITIES
9.3.1 SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET
TABLE 129 IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD BILLION)
TABLE 130 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 131 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 132 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 133 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 134 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD BILLION)
TABLE 135 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD BILLION)
9.4 OTHER END USERS
TABLE 136 IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD BILLION)
TABLE 137 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 138 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 139 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 140 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 141 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD BILLION)
TABLE 142 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD BILLION)
10 IMMUNOTHERAPY DRUGS MARKET, BY REGION (Page No. - 172)
10.1 INTRODUCTION
TABLE 143 IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2022–2029 (USD BILLION)
10.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
TABLE 144 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 145 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 146 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 147 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 148 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 US to dominate North American immunotherapy drugs market during forecast period
TABLE 149 US: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 150 US: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 151 US: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 152 US: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.2.3 CANADA
10.2.3.1 Rising government initiatives for research on regenerative medicine to drive market
TABLE 153 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 154 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 155 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 156 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.3 EUROPE
TABLE 157 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 158 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 159 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 160 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 161 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Increasing investments in healthcare research to fuel market growth
TABLE 162 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 163 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 164 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 165 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.3.3 UK
10.3.3.1 Favorable government initiatives and high R&D investments to propel market growth
TABLE 166 UK: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 167 UK: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 168 UK: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 169 UK: IMMUNOTHERAPY DRUGS THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.3.4 FRANCE
10.3.4.1 Increasing adoption of immunotherapy drugs and growing focus on healthcare R&D to augment market growth
TABLE 170 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 171 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 172 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 173 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.3.5 ITALY
10.3.5.1 Strong focus on clinical research and stringent government regulations to propel market growth
TABLE 174 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 175 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 176 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 177 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.3.6 SPAIN
10.3.6.1 Favorable government initiatives to spur market growth
TABLE 178 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 179 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
TABLE 180 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 181 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.3.7 REST OF EUROPE
TABLE 182 REST OF EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 183 REST OF EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 184 REST OF EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 185 REST OF EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.4 ASIA PACIFIC
FIGURE 30 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
TABLE 186 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 187 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 188 ASIA PACIFIC: IMMUNOTHERAPY DRUGS, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 189 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 190 ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 CHINA
10.4.2.1 Less-stringent regulatory framework and high incidence of cancer to drive market
TABLE 191 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 192 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 193 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 194 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.4.3 JAPAN
10.4.3.1 Rising geriatric population and increasing government support to augment market growth
TABLE 195 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 196 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 197 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 198 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.4.4 INDIA
10.4.4.1 Increasing prevalence of cancer and rising government healthcare investments to aid market growth
TABLE 199 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 200 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 201 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 202 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Strong biopharmaceutical sector and favorable government initiatives to support market growth
TABLE 203 SOUTH KOREA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 204 SOUTH KOREA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 205 SOUTH KOREA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 206 SOUTH KOREA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.4.6 AUSTRALIA
10.4.6.1 High prevalence of cancer and increased expenditure on health services to propel market growth
TABLE 207 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 208 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 209 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 210 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.4.7 REST OF ASIA PACIFIC
TABLE 211 REST OF ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 212 REST OF ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 213 REST OF ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 214 REST OF ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.5 LATIN AMERICA
TABLE 215 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 216 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 217 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 218 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 219 LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.5.1 LATIN AMERICA: RECESSION IMPACT
10.5.2 BRAZIL
10.5.2.1 Developed healthcare infrastructure and unified public health system to fuel market growth
TABLE 220 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 221 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 222 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 223 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 224 REST OF LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 225 REST OF LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 226 REST OF LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 227 REST OF LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.6 MIDDLE EAST
TABLE 228 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2022–2029 (USD BILLION)
TABLE 229 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 230 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 231 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 232 MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.6.1 MIDDLE EAST: RECESSION IMPACT
10.6.2 GCC COUNTRIES
TABLE 233 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)
TABLE 234 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 235 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 236 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 237 GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.6.2.1 Saudi Arabia
10.6.2.1.1 Increasing focus on R&D and growing government support to spur market growth
TABLE 238 SAUDI ARABIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 239 SAUDI ARABIA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 240 SAUDI ARABIA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 241 SAUDI ARABIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.6.2.2 UAE
10.6.2.2.1 Technological advancements and increased government focus on healthcare to support market growth
TABLE 242 UAE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 243 UAE: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 244 UAE: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 245 UAE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.6.2.3 Rest of GCC Countries
TABLE 246 REST OF GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 247 REST OF GCC COUNTRIES: IMMUNOTHERAPY DRUGS, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 248 REST OF GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 249 REST OF GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.6.3 REST OF MIDDLE EAST
TABLE 250 REST OF MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 251 REST OF MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 252 REST OF MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 253 REST OF MIDDLE EAST: IMMUNOTHERAPY DRUGS THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.7 AFRICA
10.7.1 INCREASING HEALTHCARE FUNDING AND RISING INCIDENCE OF CANCER TO DRIVE MARKET
TABLE 254 AFRICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)
TABLE 255 AFRICA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)
TABLE 256 AFRICA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)
TABLE 257 AFRICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)
10.7.2 AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE (Page No. - 239)
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOTHERAPY DRUGS MARKET
TABLE 258 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOTHERAPY DRUGS MARKET
11.3 REVENUE ANALYSIS
FIGURE 31 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOTHERAPY DRUGS MARKET (2021–2023)
11.4 MARKET SHARE ANALYSIS
FIGURE 32 MARKET SHARE ANALYSIS OF KEY PLAYERS IN IMMUNOTHERAPY DRUGS MARKET (2023)
TABLE 259 IMMUNOTHERAPY DRUGS MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 33 IMMUNOTHERAPY DRUGS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
FIGURE 34 IMMUNOTHERAPY DRUGS MARKET: COMPANY FOOTPRINT
11.5.5.2 Type footprint
TABLE 260 IMMUNOTHERAPY DRUGS MARKET: TYPE FOOTPRINT
11.5.5.3 Application footprint
TABLE 261 IMMUNOTHERAPY DRUGS MARKET: APPLICATION FOOTPRINT
11.5.5.4 Route of administration footprint
TABLE 262 IMMUNOTHERAPY DRUGS MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
11.5.5.5 Region footprint
TABLE 263 IMMUNOTHERAPY DRUGS MARKET: REGION FOOTPRINT
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
FIGURE 35 IMMUNOTHERAPY DRUGS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
TABLE 264 IMMUNOTHERAPY DRUGS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 265 IMMUNOTHERAPY DRUGS MARKET: COMPETITIVE BENCHMARKING OF KEY START UPS/SMES
11.7 COMPANY VALUATION & FINANCIAL METRICS
FIGURE 36 EV/EBITDA OF KEY PLAYERS
FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
11.8 BRAND/PRODUCT COMPARISON
FIGURE 38 IMMUNOTHERAPY DRUGS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT APPROVALS
TABLE 266 IMMUNOTHERAPY DRUGS MARKET: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
11.9.2 DEALS
TABLE 267 IMMUNOTHERAPY DRUGS MARKET: DEALS, JANUARY 2021–MAY 2024
11.9.3 OTHER DEVELOPMENTS
TABLE 268 IMMUNOTHERAPY DRUGS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12 COMPANY PROFILES (Page No. - 259)
(Business Overview, Products/Solutions/Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1 KEY PLAYERS
12.1.1 MERCK & CO., INC.
TABLE 269 MERCK & CO., INC.: COMPANY OVERVIEW
FIGURE 39 MERCK & CO., INC.: COMPANY SNAPSHOT (2023)
TABLE 270 MERCK & CO., INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 271 MERCK & CO., INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 272 MERCK & CO., INC.: DEALS, JANUARY 2021–MAY 2024
12.1.2 JOHNSON & JOHNSON SERVICES, INC.
TABLE 273 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
FIGURE 40 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2023)
TABLE 274 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 275 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 276 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2021–MAY 2024
TABLE 277 JOHNSON & JOHNSON SERVICES, INC.: EXPANSIONS, JANUARY 2021–MAY 2024
12.1.3 F. HOFFMANN-LA ROCHE LTD.
TABLE 278 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
TABLE 279 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 280 F. HOFFMANN-LA ROCHE LTD.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 281 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–MAY 2024
12.1.4 ASTRAZENECA
TABLE 282 ASTRAZENECA: COMPANY OVERVIEW
FIGURE 42 ASTRAZENECA: COMPANY SNAPSHOT (2023)
TABLE 283 ASTRAZENECA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 284 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 285 ASTRAZENECA: DEALS, JANUARY 2021–MAY 2024
TABLE 286 ASTRAZENECA: EXPANSIONS, JANUARY 2021–MAY 2024
12.1.5 PFIZER INC.
TABLE 287 PFIZER INC.: COMPANY OVERVIEW
FIGURE 43 PFIZER INC.: COMPANY SNAPSHOT (2023)
TABLE 288 PFIZER INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 289 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 290 PFIZER INC.: DEALS, JANUARY 2021–MAY 2024
12.1.6 AMGEN INC.
TABLE 291 AMGEN INC.: COMPANY OVERVIEW
FIGURE 44 AMGEN INC.: COMPANY SNAPSHOT (2023)
TABLE 292 AMGEN INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 293 AMGEN INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 294 AMGEN INC.: EXPANSIONS, JANUARY 2021–MAY 2024
12.1.7 NOVARTIS AG
TABLE 295 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 45 NOVARTIS AG: COMPANY SNAPSHOT (2023)
TABLE 296 NOVARTIS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 297 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 298 NOVARTIS AG: DEALS, JANUARY 2021–MAY 2024
12.1.8 ELI LILLY AND COMPANY
TABLE 299 ELI LILLY AND COMPANY: COMPANY OVERVIEW
FIGURE 46 ELI LILLY AND COMPANY.: COMPANY SNAPSHOT (2023)
TABLE 300 ELI LILLY AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 301 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 302 ELI LILLY AND COMPANY.: DEALS, JANUARY 2021–MAY 2024
12.1.9 SANOFI
TABLE 303 SANOFI: COMPANY OVERVIEW
FIGURE 47 SANOFI: COMPANY SNAPSHOT (2023)
TABLE 304 SANOFI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 305 SANOFI: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 306 SANOFI: DEALS, JANUARY 2021–MAY 2024
12.1.10 BRISTOL-MYERS SQUIBB COMPANY
TABLE 307 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
FIGURE 48 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2023)
TABLE 308 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 309 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 310 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2021–MAY 2024
12.1.11 GILEAD SCIENCES, INC.
TABLE 311 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
FIGURE 49 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2023)
TABLE 312 GILEAD SCIENCES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 313 GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 314 GILEAD SCIENCES, INC.: DEALS, JANUARY 2021–MAY 2024
TABLE 315 GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.1.12 TAKEDA PHARMACEUTICAL COMPANY LIMITED
TABLE 316 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
FIGURE 50 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2023)
TABLE 317 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 318 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 319 TAKEDA PHARMACEUTICAL COMPANY LIMITED: DEALS, JANUARY 2021–MAY 2024
12.1.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.
TABLE 320 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
FIGURE 51 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023)
TABLE 321 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 322 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2021–MAY 2024
12.1.14 ABBVIE INC.
TABLE 323 ABBVIE INC.: COMPANY OVERVIEW
FIGURE 52 ABBVIE INC.: COMPANY SNAPSHOT (2023)
TABLE 324 ABBVIE INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 325 ABBVIE INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 326 ABBVIE INC.: DEALS, JANUARY 2021–MAY 2024
12.1.15 GSK PLC
TABLE 327 GSK PLC: COMPANY OVERVIEW
FIGURE 53 GSK PLC: COMPANY SNAPSHOT (2023)
TABLE 328 GSK PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 329 GSK PLC: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
TABLE 330 GSK PLC: DEALS, JANUARY 2021–MAY 2024
TABLE 331 GSK PLC: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.2 OTHER PLAYERS
12.2.1 IMMUNOCORE HOLDINGS PLC
TABLE 332 IMMUNOCORE HOLDINGS PLC: COMPANY OVERVIEW
12.2.2 ASTELLAS PHARMA INC.
TABLE 333 ASTELLAS PHARMA INC.: COMPANY OVERVIEW
12.2.3 GENMAB A/S
TABLE 334 GENMAB A/S: COMPANY OVERVIEW
12.2.4 MACROGENICS, INC.
TABLE 335 MACROGENICS, INC.: COMPANY OVERVIEW
12.2.5 FERRING BV
TABLE 336 FERRING BV: COMPANY OVERVIEW
12.2.6 Y-MABS THERAPEUTICS, INC.
TABLE 337 Y-MABS THERAPEUTICS, INC.: COMPANY OVERVIEW
12.2.7 BIOGEN
TABLE 338 BIOGEN: COMPANY OVERVIEW
12.2.8 KYOWA KIRIN CO., LTD.
TABLE 339 KYOWA KIRIN CO., LTD.: COMPANY OVERVIEW
12.2.9 SWEDISH ORPHAN BIOVITRUM AB
TABLE 340 SWEDISH ORPHAN BIOVITRUM AB: COMPANY OVERVIEW
12.2.10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
TABLE 341 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 342)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
Growth opportunities and latent adjacency in Immunotherapy Drugs Market
To what extent has COVID-19 impacted the global growth of the Immunotherapy Drugs Market?